Switch theme
Sign up to access all valuation multiples
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
2006
163
LTM Revenue $29.9M
LTM EBITDA -$44.8M
$110M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rapid Micro Biosystems has a last 12-month revenue (LTM) of $29.9M and a last 12-month EBITDA of -$44.8M.
In the most recent fiscal year, Rapid Micro Biosystems achieved revenue of $28.1M and an EBITDA of -$46.6M.
Rapid Micro Biosystems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rapid Micro Biosystems valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $29.9M | XXX | $28.1M | XXX | XXX | XXX |
| Gross Profit | $1.2M | XXX | -$0.1M | XXX | XXX | XXX |
| Gross Margin | 4% | XXX | 0% | XXX | XXX | XXX |
| EBITDA | -$44.8M | XXX | -$46.6M | XXX | XXX | XXX |
| EBITDA Margin | -150% | XXX | -166% | XXX | XXX | XXX |
| EBIT | -$47.9M | XXX | -$49.9M | XXX | XXX | XXX |
| EBIT Margin | -160% | XXX | -178% | XXX | XXX | XXX |
| Net Profit | -$45.3M | XXX | -$46.9M | XXX | XXX | XXX |
| Net Margin | -151% | XXX | -167% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Rapid Micro Biosystems's stock price is $3.
Rapid Micro Biosystems has current market cap of $146M, and EV of $110M.
See Rapid Micro Biosystems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $110M | $146M | XXX | XXX | XXX | XXX | $-1.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Rapid Micro Biosystems has market cap of $146M and EV of $110M.
Rapid Micro Biosystems's trades at 3.9x EV/Revenue multiple, and -2.4x EV/EBITDA.
Equity research analysts estimate Rapid Micro Biosystems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rapid Micro Biosystems has a P/E ratio of -3.2x.
See valuation multiples for Rapid Micro Biosystems and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $146M | XXX | $146M | XXX | XXX | XXX |
| EV (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | -2.5x | XXX | -2.4x | XXX | XXX | XXX |
| EV/EBIT | -2.3x | XXX | -2.2x | XXX | XXX | XXX |
| EV/Gross Profit | 93.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.2x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | -3.0x | XXX | -2.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRapid Micro Biosystems's last 12 month revenue growth is 18%
Rapid Micro Biosystems's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Rapid Micro Biosystems's rule of 40 is -219% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rapid Micro Biosystems's rule of X is -104% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rapid Micro Biosystems and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | -150% | XXX | -166% | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -219% | XXX | -148% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -104% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 178% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rapid Micro Biosystems acquired XXX companies to date.
Last acquisition by Rapid Micro Biosystems was XXXXXXXX, XXXXX XXXXX XXXXXX . Rapid Micro Biosystems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rapid Micro Biosystems founded? | Rapid Micro Biosystems was founded in 2006. |
| Where is Rapid Micro Biosystems headquartered? | Rapid Micro Biosystems is headquartered in United States of America. |
| How many employees does Rapid Micro Biosystems have? | As of today, Rapid Micro Biosystems has 163 employees. |
| Who is the CEO of Rapid Micro Biosystems? | Rapid Micro Biosystems's CEO is Mr. Robert Spignesi. |
| Is Rapid Micro Biosystems publicy listed? | Yes, Rapid Micro Biosystems is a public company listed on NAS. |
| What is the stock symbol of Rapid Micro Biosystems? | Rapid Micro Biosystems trades under RPID ticker. |
| When did Rapid Micro Biosystems go public? | Rapid Micro Biosystems went public in 2021. |
| Who are competitors of Rapid Micro Biosystems? | Similar companies to Rapid Micro Biosystems include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Rapid Micro Biosystems? | Rapid Micro Biosystems's current market cap is $146M |
| What is the current revenue of Rapid Micro Biosystems? | Rapid Micro Biosystems's last 12 months revenue is $29.9M. |
| What is the current revenue growth of Rapid Micro Biosystems? | Rapid Micro Biosystems revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Rapid Micro Biosystems? | Current revenue multiple of Rapid Micro Biosystems is 3.7x. |
| Is Rapid Micro Biosystems profitable? | Yes, Rapid Micro Biosystems is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rapid Micro Biosystems? | Rapid Micro Biosystems's last 12 months EBITDA is -$44.8M. |
| What is Rapid Micro Biosystems's EBITDA margin? | Rapid Micro Biosystems's last 12 months EBITDA margin is -150%. |
| What is the current EV/EBITDA multiple of Rapid Micro Biosystems? | Current EBITDA multiple of Rapid Micro Biosystems is -2.5x. |
| What is the current FCF of Rapid Micro Biosystems? | Rapid Micro Biosystems's last 12 months FCF is -$37.1M. |
| What is Rapid Micro Biosystems's FCF margin? | Rapid Micro Biosystems's last 12 months FCF margin is -124%. |
| What is the current EV/FCF multiple of Rapid Micro Biosystems? | Current FCF multiple of Rapid Micro Biosystems is -3.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
